| 1 |
Hall SAL, Vogrin S, Wawryk O, Burns GS, Visvanathan K, Sundararajan V, Thompson A. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis. Gut 2022;71:1629-41. [PMID: 34493592 DOI: 10.1136/gutjnl-2020-323979] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 2 |
Ergen P, Isik B, Arslan F, Karadag FY, Aydin O, Cag Y, Yazici S, Ucisik AC, Vahaboglu MH. Outcomes of Cessation of Antiviral Therapy in Chronic Hepatitis B: A Retrospective Cohort Study. Medeni Med J 2021;36:201-8. [PMID: 34915677 DOI: 10.5222/MMJ.2021.52959] [Reference Citation Analysis]
|
| 3 |
van Bömmel F, Berg T. Hepatitis B: Wann ist eine Beendigung der Therapie mit Nukleos(t)idanaloga gerechtfertigt? Gastroenterologe 2021;16:417-432. [DOI: 10.1007/s11377-021-00572-w] [Reference Citation Analysis]
|
| 4 |
van Bömmel F, Berg T. Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg-Negative Chronic Hepatitis B. Hepatol Commun 2021;5:1632-48. [PMID: 34558833 DOI: 10.1002/hep4.1708] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 5 |
Xu WX, Li YM, Li JG, Mei YY, Chen YM, Li XJ, Lin CS, Deng H, Zhao ZX, Xie DY, Gao ZL, Peng L. The 96-week clinical outcomes after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients. Gastroenterol Rep (Oxf) 2021;9:313-22. [PMID: 34567563 DOI: 10.1093/gastro/goab013] [Reference Citation Analysis]
|
| 6 |
Kaewdech A, Sripongpun P. Challenges in the discontinuation of chronic hepatitis B antiviral agents. World J Hepatol 2021;13:1042-57. [PMID: 34630873 DOI: 10.4254/wjh.v13.i9.1042] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 7 |
Gao L, Hu Y, Shi X, Li X, Zhang D, Ren H. 48 weeks outcome after cessation of nucleos(t)ide analogue therapy in chronic hepatitis B patients. Ann Hepatol 2020;19:329-34. [PMID: 31884016 DOI: 10.1016/j.aohep.2019.10.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Xue Y, Zhang M, Li T, Liu F, Zhang LX, Fan XP, Yang BH, Wang L. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World J Gastroenterol 2021; 27(14): 1497-1506 [PMID: 33911470 DOI: 10.3748/wjg.v27.i14.1497] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 9 |
Tout I, Lampertico P, Berg T, Asselah T. Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B. Antiviral Res 2021;185:104992. [PMID: 33279523 DOI: 10.1016/j.antiviral.2020.104992] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
|
| 10 |
Hall S, Howell J, Visvanathan K, Thompson A. The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy. Viruses 2020;12:E934. [PMID: 32854335 DOI: 10.3390/v12090934] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 11 |
Wang S, Li H, Kou Z, Ren F, Jin Y, Yang L, Dong X, Yang M, Zhao J, Liu H, Dong N, Jia L, Chen X, Zhou Y, Qiu S, Hao R, Song H. Highly sensitive and specific detection of hepatitis B virus DNA and drug resistance mutations utilizing the PCR-based CRISPR-Cas13a system. Clin Microbiol Infect 2021;27:443-50. [PMID: 32360447 DOI: 10.1016/j.cmi.2020.04.018] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 12 |
Hadziyannis E, Hadziyannis S. Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B. Expert Rev Gastroenterol Hepatol 2020;14:243-51. [PMID: 32162562 DOI: 10.1080/17474124.2020.1738219] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 13 |
Bömmel F, Berg T. The stopping rules in hepatitis B virus therapy: can we provide any guidance? Clinical Dilemmas in Viral Liver Disease 2020. [DOI: 10.1002/9781119533481.ch31] [Reference Citation Analysis]
|
| 14 |
Wang XH, Jiang XM, Gao PX, Liu Q, Yuan JH, Chen SJ. Risk factors and prognostic analysis of acute-on-chronic liver failure of chronic hepatitis B after cessation of nucleos(t)ide analogs. Eur J Gastroenterol Hepatol 2020;32:265-75. [PMID: 31789948 DOI: 10.1097/MEG.0000000000001574] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 15 |
Liaw YF. Finite nucleos(t)ide analog therapy in HBeAg-negative chronic hepatitis B: an emerging paradigm shift. Hepatol Int. 2019;13:665-673. [PMID: 31559604 DOI: 10.1007/s12072-019-09989-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 9.5] [Reference Citation Analysis]
|
| 16 |
Liu Y, Jia M, Wu S, Jiang W, Feng Y. Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: A meta-analysis. Int J Infect Dis 2019;86:201-7. [PMID: 31394205 DOI: 10.1016/j.ijid.2019.07.036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 17 |
Kranidioti H, Manolakopoulos S, Kontos G, Breen MS, Kourikou A, Deutsch M, Quesada-Del-Bosque ME, Martinez-Nunez RT, Naiyer MM, Woelk CH, Sanchez-Elsner T, Hadziyannis E, Papatheodoridis G, Khakoo SI. Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic hepatitis B. J Viral Hepat 2019;26:697-709. [PMID: 30702196 DOI: 10.1111/jvh.13068] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 18 |
Buti M, Wong DK, Gane E, Flisiak R, Manns M, Kaita K, Janssen HLA, Op den Brouw M, Jump B, Kitrinos K, Crans G, Flaherty J, Gaggar A, Marcellin P. Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. Lancet Gastroenterol Hepatol. 2019;4:296-304. [PMID: 30795958 DOI: 10.1016/s2468-1253(19)30015-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 19 |
Liu F, Liu ZR, Li T, Liu Y, Zhang M, Xue Y, Zhang LX, Ye Q, Fan XP, Wang L. Varying 10-year off-treatment responses to nucleos(t)ide analogues in patients with chronic hepatitis B according to their pretreatment hepatitis B e antigen status. J Dig Dis 2018;19:561-71. [PMID: 30098114 DOI: 10.1111/1751-2980.12654] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 20 |
Xu WX, Zhang Q, Zhu X, Lin CS, Chen YM, Deng H, Mei YY, Zhao ZX, Xie DY, Gao ZL, Xie C, Peng L. 48-Week Outcome after Cessation of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patient and the Associated Factors with Relapse. Can J Gastroenterol Hepatol 2018;2018:1817680. [PMID: 29862225 DOI: 10.1155/2018/1817680] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 21 |
Moreno-Cubero E, Arco RTSD, Peña-Asensio J, Villalobos ES, Míquel J, Larrubia JR. Is it possible to stop nucleos(t)ide analogue treatment in chronic hepatitis B patients? World J Gastroenterol 2018; 24(17): 1825-1838 [PMID: 29740199 DOI: 10.3748/wjg.v24.i17.1825] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 22 |
Hu P, Shang J, Zhang W, Gong G, Li Y, Chen X, Jiang J, Xie Q, Dou X, Sun Y, Li Y, Liu Y, Liu G, Mao D, Chi X, Tang H, Li X, Xie Y, Chen X, Jiang J, Zhao P, Hou J, Gao Z, Fan H, Ding J, Zhang D, Ren H. HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog: New Switch Study. J Clin Transl Hepatol 2018;6:25-34. [PMID: 29577029 DOI: 10.14218/JCTH.2017.00072] [Cited by in Crossref: 54] [Cited by in F6Publishing: 59] [Article Influence: 10.8] [Reference Citation Analysis]
|
| 23 |
van Bömmel F, Berg T. Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B. Liver Int 2018;38 Suppl 1:90-6. [PMID: 29427489 DOI: 10.1111/liv.13654] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
|
| 24 |
Li T, Liu F, Zhang L, Ye Q, Fan X, Xue Y, Wang L. Host genetic factors in predicting response status in chronic hepatitis B patients discontinuing nucleos(t)ide analogs. Saudi J Gastroenterol 2018;24:30-6. [PMID: 29451182 DOI: 10.4103/sjg.SJG_228_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 25 |
Liu Z, Liu F, Wang L, Liu Y, Zhang M, Li T. Clinical characteristics and outcomes of patients with recurrent chronic hepatitis B after nucleos(t)ide analog withdrawal with stringent cessation criteria: A prospective cohort study. Hepatol Res 2017;47:1000-7. [PMID: 27917568 DOI: 10.1111/hepr.12836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 26 |
Kho-herman SGR, Chan HL. Stopping nucleos(t)ide analog treatment in chronic hepatitis B — Who and when? Liver Research 2017;1:135-9. [DOI: 10.1016/j.livres.2017.06.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 27 |
Matsumoto A. Hepatitis B core-related antigen: a strong indicator for cessation of nucleos(t)ide analog therapy in patients with chronic hepatitis B. J Gastroenterol 2017;52:127-8. [PMID: 27665100 DOI: 10.1007/s00535-016-1259-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 28 |
Kang SH, Kang K, Jong Eun Y, Lee YS, Kim TS, Yoo YJ, Suh SJ, Yoon EL, Jung YK, Kim JH, Seo YS, Yim HJ, Byun KS. Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients: A 10-year follow-up study. J Med Virol 2017;89:849-56. [PMID: 27769101 DOI: 10.1002/jmv.24715] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 29 |
Jeng WJ, Chen YC, Sheen IS, Lin CL, Hu TH, Chien RN, Liaw YF. Clinical Relapse After Cessation of Tenofovir Therapy in Hepatitis B e Antigen-Negative Patients. Clin Gastroenterol Hepatol 2016;14:1813-1820.e1. [PMID: 27404969 DOI: 10.1016/j.cgh.2016.07.002] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 7.7] [Reference Citation Analysis]
|
| 30 |
Yeh ML, Huang CI, Hsieh MY, Huang CF, Hsieh MH, Huang JF, Dai CY, Lin ZY, Chen SC, Yu ML, Chuang WL. Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study. Kaohsiung J Med Sci 2016;32:559-66. [PMID: 27847098 DOI: 10.1016/j.kjms.2016.08.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 31 |
Lee HA, Seo YS, Park SW, Park SJ, Kim TH, Suh SJ, Jung YK, Kim JH, An H, Yim HJ, Yeon JE, Byun KS, Um SH. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B. Clin Mol Hepatol. 2016;22:382-389. [PMID: 27729633 DOI: 10.3350/cmh.2016.0047] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 32 |
Krishnamoorthy TL, Mutimer D. Hepatitis B: encouraging the use of interferon. Curr Opin Infect Dis. 2015;28:557-562. [PMID: 26381998 DOI: 10.1097/QCO.0000000000000209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 33 |
Jung KS, Park JY, Chon YE, Kim HS, Kang W, Kim BK, Kim SU, Kim do Y, Han KH, Ahn SH. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. J Gastroenterol 2016;51:830-9. [PMID: 26687058 DOI: 10.1007/s00535-015-1153-1] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 9.7] [Reference Citation Analysis]
|
| 34 |
Papatheodoridis G, Vlachogiannakos I, Cholongitas E, Wursthorn K, Thomadakis C, Touloumi G, Petersen J. Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. Hepatology 2016;63:1481-92. [PMID: 27100145 DOI: 10.1002/hep.28438] [Cited by in Crossref: 184] [Cited by in F6Publishing: 189] [Article Influence: 26.3] [Reference Citation Analysis]
|
| 35 |
Nagata N, Kagawa T, Hirose S, Arase Y, Tsuruya K, Anzai K, Shiraishi K, Mine T. Off-treatment durability of antiviral response to nucleoside analogues in patients with chronic hepatitis B. BMC Gastroenterol 2016;16:38. [PMID: 26987437 DOI: 10.1186/s12876-016-0454-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 36 |
Lin CC, Bair MJ, Chen CJ, Lee KH, Chen MJ, Liu CY, Chang CW, Hu KC, Liou TC, Lin SC, Wang HY, Chu CH, Shih SC, Wang TE. Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients. Kaohsiung J Med Sci 2016;32:10-5. [PMID: 26853169 DOI: 10.1016/j.kjms.2015.11.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 37 |
Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH; American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology 2016;63:261-83. [PMID: 26566064 DOI: 10.1002/hep.28156] [Cited by in Crossref: 1383] [Cited by in F6Publishing: 1451] [Article Influence: 197.6] [Reference Citation Analysis]
|
| 38 |
Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1-98. [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4] [Cited by in Crossref: 1348] [Cited by in F6Publishing: 1457] [Article Influence: 168.5] [Reference Citation Analysis]
|
| 39 |
Chen CH, Hung CH, Hu TH, Wang JH, Lu SN, Su PF, Lee CM. Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection. Clin Gastroenterol Hepatol 2015;13:1984-92.e1. [PMID: 26073492 DOI: 10.1016/j.cgh.2015.06.002] [Cited by in Crossref: 73] [Cited by in F6Publishing: 74] [Article Influence: 9.1] [Reference Citation Analysis]
|
| 40 |
Chen L, Gan QR, Zhang DQ, Yao LF, Lin RS, Li Q, Lin MH, Yu DM, Zhang XX, Pan C. Increased intrahepatic quasispecies heterogeneity correlates with off-treatment sustained response to nucleos(t)ide analogues in e antigen-positive chronic hepatitis B patients. Clin Microbiol Infect 2016;22:201-7. [PMID: 26493847 DOI: 10.1016/j.cmi.2015.10.007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 41 |
Siakavellas SI, Papatheodoridis GV. Controversial Issues in Current Treatment of Chronic HBV Infection. Curr Hepatology Rep 2015;14:164-170. [DOI: 10.1007/s11901-015-0268-4] [Reference Citation Analysis]
|
| 42 |
Chang ML, Liaw YF, Hadziyannis SJ. Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2015;42:243-57. [PMID: 26151841 DOI: 10.1111/apt.13272] [Cited by in Crossref: 95] [Cited by in F6Publishing: 68] [Article Influence: 11.9] [Reference Citation Analysis]
|
| 43 |
Ge GH, Ye Y, Zhou XB, Chen L, He C, Wen DF, Tan YW. Hepatitis B surface antigen levels of cessation of nucleos(t)ide analogs associated with virological relapse in hepatitis B surface antigen-negative chronic hepatitis B patients. World J Gastroenterol 2015; 21(28): 8653-8659 [PMID: 26229407 DOI: 10.3748/wjg.v21.i28.8653] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 44 |
Chang ML, Jeng WJ, Liaw YF. Clinical events after cessation of lamivudine therapy in patients recovered from hepatitis B flare with hepatic decompensation. Clin Gastroenterol Hepatol 2015;13:979-86. [PMID: 25445774 DOI: 10.1016/j.cgh.2014.10.023] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 45 |
Yeh ML, Peng CY, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients. PLoS One. 2015;10:e0122259. [PMID: 25835020 DOI: 10.1371/journal.pone.0122259] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 46 |
Seto WK, Hui AJ, Wong VW, Wong GL, Liu KS, Lai CL, Yuen MF, Chan HL. Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study. Gut 2015;64:667-72. [PMID: 24833635 DOI: 10.1136/gutjnl-2014-307237] [Cited by in Crossref: 155] [Cited by in F6Publishing: 158] [Article Influence: 19.4] [Reference Citation Analysis]
|
| 47 |
Martín Mateos RM, Moreira Vicente VF, Tavío Hernández E, Cuño Roldán JL, Téllez Villajos L, Aicart Ramos M, Arribas Anta J, Zaera de la Fuente C, Albillos Martínez A. [Is it possible to stop treatment with nucleos(t)ide analogs in patients with e-antigen negative chronic hepatitis B? Experience and new expectations]. Gastroenterol Hepatol 2015;38:305-12. [PMID: 25636371 DOI: 10.1016/j.gastrohep.2014.12.001] [Reference Citation Analysis]
|
| 48 |
Peng J, Cao J, Yu T, Cai S, Li Z, Zhang X, Sun J. Predictors of sustained virologic response after discontinuation of nucleos(t)ide analog treatment for chronic hepatitis B. Saudi J Gastroenterol 2015;21:245-53. [PMID: 26228369 DOI: 10.4103/1319-3767.161645] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 49 |
Okonkwo UC, Onyekwere CA. Challenges in the management of chronic HBV infection in West Africa: The clinician's perspective. Trop Doct 2016;46:16-20. [PMID: 25505192 DOI: 10.1177/0049475514561822] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 50 |
Patwardhan VR, Sengupta N, Bonder A, Lau D, Afdhal NH. Treatment cessation in noncirrhotic, e-antigen negative chronic hepatitis B is safe and effective following prolonged anti-viral suppression with nucleosides/nucleotides. Aliment Pharmacol Ther 2014;40:804-10. [PMID: 25109610 DOI: 10.1111/apt.12908] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 51 |
Chen CH, Lu SN, Hung CH, Wang JH, Hu TH, Changchien CS, Lee CM. The role of hepatitis B surface antigen quantification in predicting HBsAg loss and HBV relapse after discontinuation of lamivudine treatment. J Hepatol 2014;61:515-22. [PMID: 24798617 DOI: 10.1016/j.jhep.2014.04.029] [Cited by in Crossref: 116] [Cited by in F6Publishing: 118] [Article Influence: 12.9] [Reference Citation Analysis]
|
| 52 |
Sohn HR, Min BY, Song JC, Seong MH, Lee SS, Jang ES, Shin CM, Park YS, Hwang JH, Jeong SH, Kim N, Lee DH, Kim JW. Off-treatment virologic relapse and outcomes of re-treatment in chronic hepatitis B patients who achieved complete viral suppression with oral nucleos(t)ide analogs. BMC Infect Dis. 2014;14:439. [PMID: 25125320 DOI: 10.1186/1471-2334-14-439] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 53 |
Chen CH, Chiu YC, Lu SN, Lee CM, Wang JH, Hu TH, Hung CH. Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues. World J Gastroenterol 2014; 20(24): 7686-7695 [PMID: 24976706 DOI: 10.3748/wjg.v20.i24.7686] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 26] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 54 |
Kang W, Park JY. When to stop nucleos(t)ide analogues treatment for chronic hepatitis B? Durability of antiviral response. World J Gastroenterol 2014; 20(23): 7207-7212 [PMID: 24966590 DOI: 10.3748/wjg.v20.i23.7207] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 55 |
Hyeong Lee C. Oral Antiviral Therapy for Chronic Hepatitis B Virus Infection: Is Continuous Treatment Needed? GHOA 2014;1. [DOI: 10.15406/ghoa.2014.01.00005] [Reference Citation Analysis]
|
| 56 |
Hadziyannis SJ, Vassilopoulos D, Sevastianos V, Hadziyannis E. Can Nucleos(t)ide Analogue (NA) Therapy Ever be Stopped in HBeAg-Negative Chronic Hepatitis B? Curr Hepatology Rep 2014;13:256-63. [DOI: 10.1007/s11901-014-0236-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 57 |
He D, Guo S, Zhu P, Tao S, Li M, Huang H, Wang J, Wang Y, Ding M. Long-term outcomes after nucleos(t)ide analogue discontinuation in HBeAg-positive chronic hepatitis B patients. Clin Microbiol Infect. 2014;20:O687-O693. [PMID: 25469947 DOI: 10.1111/1469-0691.12605] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 58 |
Chen D, Chen Y, Liu J, Xie D, Lu C, Huang Z, Zhu R, Gao Z. Durability of efficacy after telbivudine off-treatment in chronic hepatitis B patients. Journal of Clinical Virology 2014;59:50-4. [DOI: 10.1016/j.jcv.2013.11.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
|
| 59 |
Chen EQ, Bai L, Chen LL, Zhou TY, Du LY, Tang H. Prolonged Combination Therapy is More Effective than Monotherapy in Management of Chronic Hepatitis B Patients With Sustained Virological Response: An Experience From a 'Real-World' Clinical Setting. Iran Red Crescent Med J 2013;15:e7788. [PMID: 24693412 DOI: 10.5812/ircmj.7788] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 60 |
Jeng WJ, Sheen IS, Chen YC, Hsu CW, Chien RN, Chu CM, Liaw YF. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 2013;58:1888-96. [PMID: 23744454 DOI: 10.1002/hep.26549] [Cited by in Crossref: 177] [Cited by in F6Publishing: 185] [Article Influence: 17.7] [Reference Citation Analysis]
|
| 61 |
He D, Guo S, Chen W, Chen X, Yan G, Wang J, Li M, Zhu P, Huang H, Wang Y. Long-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negative. BMC Infect Dis. 2013;13:458. [PMID: 24090287 DOI: 10.1186/1471-2334-13-458] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 62 |
Kim YJ, Kim K, Hwang SH, Kim SS, Lee D, Cheong JY, Cho SW. Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients. Clin Mol Hepatol. 2013;19:300-304. [PMID: 24133668 DOI: 10.3350/cmh.2013.19.3.300] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 63 |
Ouzan D, Pénaranda G, Joly H, Khiri H, Pironti A, Halfon P. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs. J Clin Virol. 2013;58:713-717. [PMID: 24183313 DOI: 10.1016/j.jcv.2013.09.020] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 64 |
Wong GL, Chong C, Wong VW. Tertiary Prevention of HBV-related HCC in Asia. Curr Hepatitis Rep 2013;12:157-164. [DOI: 10.1007/s11901-013-0171-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 65 |
Peng C. Nucleos(t)ide Analogues Therapy for Chronic Hepatitis B in Taiwan: Short-Term Versus Long-Term. Curr Hepatitis Rep 2013;12:181-187. [DOI: 10.1007/s11901-013-0173-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 66 |
Chan WK, Tan S, Mohamed R. Stopping Therapy in HBeAg Negative Disease. Curr Hepatitis Rep 2013;12:105-11. [DOI: 10.1007/s11901-013-0167-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 67 |
Hadziyannis SJ, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012;143:629-636.e1. [PMID: 22659218 DOI: 10.1053/j.gastro.2012.05.039] [Cited by in Crossref: 232] [Cited by in F6Publishing: 237] [Article Influence: 21.1] [Reference Citation Analysis]
|
| 68 |
Kozuka R, Enomoto M, Morikawa H, Tamori A, Kawada N. Anti-hepatitis B virus therapy: To stop, or not to stop: Has the question been solved? Hepatol Res 2012;42:946-7. [PMID: 22882339 DOI: 10.1111/j.1872-034X.2012.01001.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 69 |
Korean Association for the Study of the Liver. KASL Clinical Practice Guidelines: Management of chronic hepatitis B. Clin Mol Hepatol. 2012;18:109-162. [PMID: 22893865 DOI: 10.3350/cmh.2012.18.2.109] [Cited by in Crossref: 116] [Cited by in F6Publishing: 138] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 70 |
Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531-561. [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4] [Cited by in Crossref: 742] [Cited by in F6Publishing: 688] [Article Influence: 67.5] [Reference Citation Analysis]
|
| 71 |
Matsumoto A, Tanaka E, Suzuki Y, Kobayashi M, Tanaka Y, Shinkai N, Hige S, Yatsuhashi H, Nagaoka S, Chayama K, Tsuge M, Yokosuka O, Imazeki F, Nishiguchi S, Saito M, Fujiwara K, Torii N, Hiramatsu N, Karino Y, Kumada H. Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B. Hepatol Res 2012;42:139-49. [PMID: 22103237 DOI: 10.1111/j.1872-034X.2011.00910.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 72 |
Ha M, Zhang G, Diao S, Lin M, Sun L, She H, Kuan C, Shen L, Huang C, Shen W. A prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients with stringent cessation criteria for adefovir. Arch Virol. 2012;157:285-290. [PMID: 22080196 DOI: 10.1007/s00705-011-1163-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 73 |
Liang Y, Jiang J, Su M, Liu Z, Guo W, Huang X, Xie R, Ge S, Hu J, Jiang Z, Zhu M, Wong VW, Chan HL. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther 2011;34:344-52. [PMID: 21671967 DOI: 10.1111/j.1365-2036.2011.04738.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 73] [Article Influence: 8.1] [Reference Citation Analysis]
|
| 74 |
Fung J, Lai CL, Yuen MF. To stop or not to stop: the quest for long-term viral suppression. J Gastroenterol Hepatol 2011;26:420-2. [PMID: 21332537 DOI: 10.1111/j.1440-1746.2011.06604.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
